New FLEXYTEŽ Protease Assays enable information-rich output, miniaturization and multiplexing
Almac launches FLEXYTEŽ protease assay platform - the next step in utilization of fluorescent lifetime technology - at the 2010 Society for Biomolecular Sciences (SBS) meeting in Phoenix (11-15 April)
The new FLEXYTEŽ protease assays follow on from the great success of FLEXYTEŽ protein kinase assays launched in 2009. FLEXYTEŽ protease assays harness the power and potential of fluorescence lifetime technology for robust, efficient and economical screening of proteases. Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, robust and reliable assays with minimized interference from problem compounds, and will allow miniaturization, and multiplexing, while maintaining an information-rich output.
FLEXYTEŽ protease assays are based on labelled peptide substrates which have been developed for a variety of proteases. The generic peptide approach enables FLEXYTEŽ protease assays to be configured for a broad range of proteases. Almac will provide a custom assay development service for any protease of interest to customers.
Commenting on the launch of FLEXYTEŽ protease assays, Almac Sciences President and Managing Director, Stephen Barr said: FLEXYTEŽ protease assays represent the next step in utilization of fluorescent lifetime technology to produce more robust, reliable and efficient assays in therapeutically important target classes.
Almac will be exhibiting at the SBS meeting and will be available to provide more information on FLEXYTEŽ protease and protein kinase assays at booth 229.